Pietro Di Tondo joins ReFaC

The specialist regulatory compliance company appoints a new Technical Officer

ReFaC, the specialist regulatory compliance company of the Chemical Business Association (CBA), has appointed Pietro Di Tondo as its new Technical Officer.

Di Tondo was formerly Product Safety Assistant with a multinational company acting as a product safety advisor to a variety of market sectors. He also advised on the Classification, Labelling and Packaging Regulations (CLP) and acted as HAZARD communicator to marketing, sales, technical and regulatory groups.

You may also like

Regulatory

Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer

The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
Sustainability

ten23 health achieves B Corp status

The acknowledgement makes the ten23 the first biotech CDMO to receive this status
Regulatory

Roche's cancer immunotherapy Tecentriq Hybreza bags FDA approval

The drug first and only subcutaneous PD-(L)1 inhibitor available for patients with certain types of lung, skin, liver and soft tissue cancers
Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally
Regulatory

SeaBeLife's SBL01 acute liver failure drug candidate receives ODD from the EMA

The small molecule acts as a necrosis and ferroptosis inhibitor, allowing for the protection and restoration of liver cells in those with acute liver failure
Regulatory

Johnson & Johnson submits nipocalimab application to the FDA following positive Phase III results

The drug — in combination with the standard of care regimen — was able to exhibit sustained disease control over the 24 week trial period
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Subscribe now